The Next Wave Of M&A Sweeps In, Bringing Novel Approaches That May Be Here To Stay
Executive Summary
The first half of 2014 has been one wild M&A ride for the pharma industry, with some of the most valuable deals pharma has seen in years proposed. They have involved everything from asset swaps to mega-mergers, activist investors and tax inversion strategies, suggesting industry is testing different approaches to address a similar challenge: increasing pressure from payers to reduce health care and drug spending.
You may also be interested in...
Actavis’ Big Bet On Diversified Hybrid Model Reflects Industry Trends
Actavis’ proposal to buy Forest Labs for $25 billion in stock and cash was driven by consolidating customers and fierce competition in traditional Western markets. Different pressures, namely the tough-to-manage patent cliff, as well as leadership succession issues and investor unrest, drove Forest into the arms of a suitor.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.